Boris Lvin (bbb) wrote,
Boris Lvin

Пишут, что

Nes Ziona, Israel, Oct. 01, 2020 (GLOBE NEWSWIRE)

Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the "Company"), a clinical-stage immunotherapy company, today reported positive top-line results of an investigator-initiated clinical trial of Allocetra in COVID-19 patients in severe/critical condition.

The clinical trial included five COVID-19 patients, three in severe condition and two in critical condition. All five patients had complete recovery from their respective severe/critical condition and were released from the hospital after an average of 5.5 days (severe) and 8.5 days (critical), following administration of Allocetra, at which time they were all COVID-19 PCR negative. There were no reported severe adverse events relating to the administration of Allocetra in the patients, and the therapy was well-tolerated.

АПДЕЙТ: Запустили вторую фазу испытаний

АПДЕЙТ-2: Первые два пациента получили препарат

АПДЕЙТ-3 - 3 декабря

Allocetra-OTS in COVID-19, Phase II

АПДЕЙТ-4 - 3 февраля
Tags: virus

  • Post a new comment


    default userpic

    Your reply will be screened

    Your IP address will be recorded 

    When you submit the form an invisible reCAPTCHA check will be performed.
    You must follow the Privacy Policy and Google Terms of use.